Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections

C Buddy Creech; Susan E Beekmann; YiYi Chen; Philip M Polgreen

doi:10.1097/INF.0b013e31815c9068

Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Pediatr Infect Dis J. 2008 Mar;27(3):270-2. doi: 10.1097/INF.0b013e31815c9068.

Authors

C Buddy Creech¹, Susan E Beekmann, YiYi Chen, Philip M Polgreen

Affiliation

¹ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. [email protected]

PMID: 18277924
DOI: 10.1097/INF.0b013e31815c9068

Abstract

There are currently no clear consensus recommendations for the treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections in pediatric patients. We surveyed over 100 Pediatric Infectious Diseases consultants and found considerable variability in both the treatment of skin and soft tissue infections and the strategies used for the management of children with recurrent MRSA disease.

MeSH terms

Community-Acquired Infections / drug therapy
Community-Acquired Infections / microbiology
Community-Acquired Infections / prevention & control
Health Services / standards*
Humans
Methicillin Resistance*
Soft Tissue Infections / drug therapy*
Soft Tissue Infections / microbiology
Soft Tissue Infections / prevention & control*
Specialization
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / microbiology
Staphylococcal Infections / prevention & control*
Staphylococcal Skin Infections / drug therapy*
Staphylococcal Skin Infections / microbiology
Staphylococcal Skin Infections / prevention & control*
Staphylococcus aureus / drug effects